Microbial screening methods for detection of antibiotic residues in slaughter animals by Pikkemaat, M.G.
REVIEW
Microbial screening methods for detection of antibiotic
residues in slaughter animals
Mariël G. Pikkemaat
Received: 23 February 2009 /Revised: 5 May 2009 /Accepted: 7 May 2009 /Published online: 30 May 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract Monitoring of food products from animal origin
for the presence of antimicrobial residues is preferably done
using microbial screening methods because of their high
cost-effectiveness. Traditionally applied methods fail to
detect the maximum residue limits which were established
when EU Council Regulation 2377/90 came into effect.
Consequently, during the last decade this has led to the
development of improved microbial screening methods.
This review provides an overview of the efforts expended
to bring antibiotic screening methods into compliance with
EU legislation. It can be concluded that the current situation
is still far from satisfactory.
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Introduction
Antibiotics are widely used in veterinary medicine and
subsequently drug residues may persist in foods derived
from animals, which may pose an adverse health effect for
the consumer. Screening of food products from animal
origin for the presence of antimicrobial residues started
soon after the introduction of antibacterial therapy in
veterinary medicine. Initially it mainly concerned process
monitoring in the dairy industry to prevent problems in
fermentative dairy production, but from the early 1970s
regulatory residue screening in slaughter animals also
became more commonly introduced.
An efficient screening method needs to be low-cost and
high-throughput, able to effectively identify potential non-
compliant samples from a large set of negative samples.
Microbial inhibitions assays were the earliest methods
used for the detection of antibiotic residues [1, 2] and they
are still widely used. They are very cost-effective and in
contrast to, for example, immunological or receptor-based
tests, they have the potential to cover the entire antibiotic
spectrum within one test. Two main test formats can be
distinguished: the tube test and the (multi-) plate test. A
tube (or vial, or ampoule) test consists of a growth medium
inoculated with (spores of) a sensitive test bacterium,
supplemented with a pH or redox indicator. At the
appropriate temperature, the bacteria start to grow and
produce acid, which will cause a color change. The
presence of antimicrobial residues will prevent or delay
bacterial growth, and thus is indicated by the absence or
delay of the color change. This format is commonly applied
in routine screening of milk [3, 4], but it is also increasingly
used for analysis of other matrices [5–7]. A plate test
consists of a layer of inoculated nutrient agar, with samples
applied on top of the layer, or in wells in the agar. Bacterial
growth will turn the agar into an opaque layer, which yields
a clear growth-inhibited area around the sample if it
contains antimicrobial substances. In Europe this has been
the main test format since screening of slaughter animals
for the presence of antibiotics started [8, 9].
One of the first official methods was the Sarcina lutea
kidney test of van Schothorst [10], which became the
statutorily prescribed method in the Netherlands in 1973.
At approximately the same time, Germany introduced a
Bacillus subtilis BGA test and other countries adopted
similar test methods [8]. In 1980 a standardized method for
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the detection of antibacterial substances was proposed by a
working group of the Scientific Veterinary Commission of
the European Commission [9]. This EU four-plate test
(EU4pt) comprises three plates of agar medium inoculated
with B. subtilis BGA spores at pH 6, 7.2, and 8, and a
Kocuria rhizophila (formerly known as Micrococcus luteus
[11]) ATCC 9341 plate at pH 8. The pH 7.2 medium is
supplemented with trimethoprim (TMP) to increase the
sensitivity for sulfonamides. For a long time the result of
this test was used as an unofficial tolerance level: meat
testing negative on all four test plates was considered
compliant.
The EU4pt was developed for detection of residues
in meat and was considered less suitable for analysis of
kidney because it caused too many false-positive results
with this matrix. Also a test comprising four plates was
considered rather laborious, so in several countries one-
plate alternatives were introduced [12–14]. These tests,
based on B. subtilis, used renal pelvis fluid or kidney as a
test matrix, since residue levels in this organ are generally
higher than in meat, allowing a somewhat reduced
sensitivity of the test, while the results were still
comparable with the EU4pt results for meat [12].
Introduction of a membrane between the kidney sample
and the test plate was used to prevent problems with
natural growth-inhibiting compounds [14].
Ongoing harmonization of European legislation has led
to a collective approach with respect to the approval of
veterinary drugs (EU Council Regulation 2377/90 [15]) and
monitoring programs (EU Council Directive 96/23/EC
[16]). Before a veterinary medicinal product is allowed on
the market, it has to undergo a safety and residue
evaluation, after which maximum residue limits (MRLs)
can be defined. This process started in 1992 and currently
the list of antibacterial substances (category B1 substances)
for which an MRL has been established comprises over 50
antimicrobial compounds (Table 1). EU Council Directive
96/23/EC prescribes mandatory screening of a fixed
percentage of all animal products for the presence of
residues of antimicrobial drugs. The vast majority of the
screening methods used for monitoring the presence of
antimicrobial compounds today are still microbial inhibi-
tion tests [17]. However, the establishment of MRLs has
made us reconsider the original microbial screening
methods, such as the EU4pt and one-plate B. subtilis
assays, employed in the pre-MRL era, as it should be
concluded that for many residues these tests are insuffi-
ciently sensitive [12, 18, 19].
Consequently the last decade has shown a significant
development of improved methods. This paper reviews the
efforts to develop methods that are (as far as possible) in
compliance with EU legislation. An overview of the
methods referred to is provided in Table 2.
Method development
Multiplate (broad-spectrum) methods
The most important trend that can be observed in the
development of microbial detection methods for antibiotics
is acknowledgement of the fact that adequate detection of a
broad spectrum of antibiotics is only possible using multi-
plate assays based on a combination of different test
bacteria.
Okerman et al. [20] presented an inhibition test for
detection and presumptive identification of tetracyclines, β-
lactams, and quinolones in poultry. The method comprises
three pH 6 plates, inoculated with B. cereus, K. rhizophila,
and Escherichia coli. The detection limits of a limited
number of residues were compared with those of a B.
subtilis pH 6 test and were found to be lower for all
compounds, although the differences between B. subtilis
and B. cereus sensitivity for tetracyclines were remarkably
small. As the authors mentioned, this method should be
considered a limited-spectrum method, because amino-
glycosides and sulfonamides will not be detected. Also
adequate detection of macrolides would probably require a
higher pH.
Tsai and Kondo [21] evaluated the detection levels of 31
antimicrobial agents on various combinations of seven
bacteria and five media. These included the somewhat
uncommon test organisms Clostridium perfringens and
Photobacterium phosphoreum. On the basis of the results
a method comprising B. stearothermophilus, B. subtilis , K.
rhizophila, and E. coli was proposed. B. cereus was
included in the evaluation but was not found to be essential
as B. subtilis grown on minimum medium showed better
sensitivity to the tetracyclines tested (oxytetracycline
(OTC) and chlortetracycline).
An interesting study was presented by Myllyniemi et al.
[22], who evaluated the regulatory prescribed Finnish two-
plate test, supplemented with a B. subtilis pH 7.2 + TMP
plate. Kidney and muscle were taken from animals that
were emergency-slaughtered during the withdrawal period
of an antibiotic treatment. The samples were chemically
confirmed, and the 68 out of 89 animals that contained
residues showed a wide range of penicillin, OTC, and
enrofloxacin concentrations below and above the MRL.
This study provided valuable data on the correlation
between the concentrations found in kidney and muscle in
the same carcass. It was concluded that the B. subtilis
assays used were not sensitive enough to allow OTC and
enrofloxacin screening in muscle; only penicillin could be
screened adequately from muscle tissue.
The costs of chemical confirmation can be considerably
reduced by introducing a preliminary microbial identifica-
tion procedure. For this reason the activity patterns of 15
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Table 1 Overview of EU maximum residue limits (MRLs) (μg kg−1), established until 1 January 2009
Pharmacologically
active substance
Animal species Commission
regulation
Target tissues Milk Egg Honey
Muscle Fat Liver Kidney
β-Lactam antibiotics
Amoxicillin All food-producing species 508/1999 50 50 50 50 4
Ampicillin All food-producing species 508/1999 50 50 50 50 4
Benzylpenicillin All food-producing
species
508/1999 50 50 50 50 4
Cefacetril Bovine 2162/2001 125
Cefalexin Bovine 2728/1999 200 200 200 1,000 100
Cefapirin Bovine 1553/2001 50 50 100 60
Cefazolin Bovine, ovine, caprine 508/1999 50
Cefoperazon Bovine 807/2001 50
Cefquinome Bovine, porcine,
Equidae
508/1999,
1931/1999,
2145/2003
50 50 100 200 20
Ceftiofur All mammalian
food-producing
species
1231/2006 1,000 2,000 2,000 6,000 100
Cloxacillin All food-producing species 508/1999 300 300 300 300 30
Dicloxacillin All food-producing species 508/1999 300 300 300 300 30
Fenoxymethylpenicillin Porcine 1286/2000 25 25 25
Fenoxymethylpenicillin Poultry 1299/2005 25 25 25 25
Nafcillin All ruminants 546/2004 300 300 300 300 30
Oxacillin All food-producing
species
508/1999 300 300 300 300 30
Penethamate All mammalian
food-producing
species
1148/2005 50 50 50 50 4
Aminoglycosides
Apramycin Bovine 1931/1999 1,000 1,000 10,000 20,000
Dihydrostreptomycin All ruminants, porcine, rabbits 703/2007 500 500 500 1000 200
Gentamicin Bovine, porcine 868/2002 50 50 200 750 100
Kanamycin All food-producing species,
except fish
324/2004 100 100 600 2,500 150
Neomycin All ood-producing species 1181/2002 500 500 500 5,000 1,500 500
Paromomycin All food producing species 1181/2002 500 1,500 1,500
Spectinomycin Ovine 1181/2002 300 500 2,000 5,000 200
Spectinomycin Other food-producing
species
1181/2002 300 500 1,000 5,000 200
Streptomycin All ruminants, porcine,
rabbits
703/2007 500 500 500 1,000 200
Tetracyclines
Chlortetracycline All food-producing species 508/1999 100 300 600 100 200
Doxycycline bovine, porcine, poultry 508/1999 100 300 300 600
Oxytetracycline All food-producing species 508/1999 100 300 600 100 200
Tetracycline All food-producing species 508/1999 100 300 600 100 200
Macrolides
Erythromycin All food-producing species 1181/2002 200 200 200 200 40 150
Gamithromycina Bovine 203/2008 20 200 100
Spiramycin Bovine 508/1999 200 300 300 300 200
Spiramycin Chicken 508/1999 200 300 400
Spiramycin Porcine 2593/1999 250 2,000 1,000
Tilmicosin Poultry 1181/2002 75 75 1,000 250
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Table 1 (continued)
Pharmacologically
active substance
Animal species Commission
regulation
Target tissues Milk Egg Honey
Muscle Fat Liver Kidney
Tilmicosin Other food producing species 1181/2002 50 50 1,000 100 50
Tulathromycin Bovine, porcine 1101/2004 100 3,000 3,000
Tylosin All food-producing species 1181/2002 100 100 100 100 50 200
Tylvalosinb Porcine 1353/2007 50 50 50 50
Tylvalosinb Poultry 1353/2007 50 50
Pleuromutilins
Tiamulin Porcine, rabbits 2728/1999,
2338/2000
100 500
Tiamulin Chicken 2728/1999 100 100 1,000 1,000
Tiamulin Turkey 807/2001 100 100 300
Valnemulin Porcine 508/1999 50 500 100
Lincosamides
Lincomycin All food-producing species 1181/2002 100 50 500 1,500 150 50
Pirlimycin Bovine 2338/2000 100 100 1,000 400 100
Quinolones
Danofloxacin Bovine, ovine,
caprine, poultry
1181/2002 200 100 400 400 30
Danofloxacin Other food producing species 1181/2002 100 50 200 200
Difloxacin Bovine, ovine, caprine 1181/2002 400 100 1400 800
Difloxacin Porcine 1181/2002 100 100 800 800
Difloxacin Poultry 1181/2002 300 400 1,900 600
Difloxacin Other food-producing species 1181/2002 300 100 800 600
Enrofloxacin Bovine, ovine, caprine 1181/2002 100 100 300 200 100
Enrofloxacin Porcine, poultry, rabbits 1181/2002 100 100 200 300
Flumequine Bovine, porcine, ovine,
caprine
1181/2002 200 300 500 1,500 50
Flumequine Poultry 1181/2002 400 250 800 1,000
Flumequine Fin fish 1181/2002 600
Marbofloxacin Bovine, porcine 2338/2000 150 50 150 150 75
Oxolinic acid All food-producing species 1356/2005 100 50 150 150
Sarafloxacin Chicken 508/1999 10 100
Sarafloxacin Salmonidae 508/1999 30
Sulfonamides All food-producing species 508/1999 100 100 100 100 100
Diaminopyrimidines
Trimethoprim Equidae 1181/2002 100 100 100 100
Trimethoprim Other food-producing species 1181/2002 50 50 50 50 50
Baquiloprim Bovine 508/1999 10 300 150 30
Baquiloprim Porcine 508/1999 40 50 50
Chloramphenicol analogs
Florfenicol Bovine, ovine, caprine 1181/2002 200 3,000 300
Florfenicol Porcine 1181/2002 300 500 2,000 500
Florfenicol Fin fish 1181/2002 1,000
Florfenicol Poultry 1181/2002 100 200 2,500 750
Thiamphenicol All food-producing species 1805/2006 50 50 50 50 50
Ionophores
Lasalocide Poultry 1353/2007 20 100 100 50 150
Monensin Bovine 1353/2007 2 10 30 2 2
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different antibiotics were assessed on 18 combinations of
test bacteria, varying growth medium pH values and
antagonistic compounds [23]. This approach generated data
for these specific antibiotics on a wide range of test plates,
yielding a much better view of the specificity of a test plate.
Activity patterns appeared to be sufficiently specific for
group identification of the antibiotics tested. Additional
data were generated with incurred kidney and muscle
samples containing penicillin, OTC, and enrofloxacin
(including the metabolite ciprofloxacin) and for these
compounds the microbiological identification and the
chemical identification were in good agreement. Cluster
analysis on the inhibition zones caused by the different
antimicrobial compounds on each of the 18 test plates
revealed that the number of plates required for effective
preliminary identification could be narrowed down to six
[24]. It was shown that group identification of standard
solutions and incurred samples of penicillin, OTC, and
enrofloxacin remained correct; unfortunately no data for the
other antibiotic groups are available.
The possibility for preliminary identification from
activity profiles was also explored for the US Food Safety
and Inspection Service (USDA-FSIS) method [25, 26]. This
method consists of seven test plates and is used by the
USDA-FSIS as a microbial confirmatory procedure for
samples which tested positive in initial screening tests such
as STOP [27], CAST [28], and FAST [29]. The method
does not use the commonly applied K. rhizophila ATCC
9341, but uses two erythromycin- or (dihydro)streptomy-
cin-resistant derivatives, which may improve the identifi-
cation of macrolides and aminoglycosides. The method
lacks a TMP-supplemented test plate and should therefore
be considered insufficient with respect to the detection of
sulfonamides. The B. subtilis plate in this method allows
adequate detection of enrofloxacin. However, the lack of a
specific test plate for this antibiotic group will probably
lead to a situation in which most other veterinary
quinolones remain undetected.
Under EU Council Directive 96/23/EC, AFSSA Fou-
gères was designated as the Community Reference Labo-
ratory (CRL) for (among others) the B1 substances [16].
The CRL proposed an improved method for screening of
meat, the screening test for antibiotic residues (STAR) [30,
31], which is based on five individual test plates containing
B. cereus, B. stearothermophilus, B. subtilis, K. rhizophila,
and E. coli as the indicator organisms. The results of an
initial collaborative study with a small number of residues
in pig muscle were mainly satisfactorily, although genta-
micin at 5 times the MRL was not detected and the B.
stearothermophilus plate showed inhibition with blank
samples [30]. Additionally the STAR was validated with
fortified milk samples [31]. The compounds that could not
be detected at levels less than or equal to the MRL were
mainly sulfonamides and β-lactams; for the latter group,
however, the MRLs in milk are generally lower than MRLs
for other matrices. A validation study with spiked muscle
tissue samples is ongoing, but preliminary results show that
the detection capability for several of the substances tested
appears to exceed the MRL [32].
Ferrini et al. [33] presented a six-plate method, the
combined plate microbial assay (CPMA), which essentially
consists of the EU4pt, extended with additional B. cereus
and E. coli plates. When the proposed strategy is applied,
i.e., applying samples in twofold or fourfold and supple-
menting them with one of the confirmatory solutions
penicillinase, 4-aminobenzoate, or magnesium sulfate, the
test allows presumptive group identification and initial
screening in one step. This same approach was presented
earlier for a limited range of residue groups in milk [34]
and meat [35].
Table 1 (continued)
Pharmacologically
active substance
Animal species Commission
regulation
Target tissues Milk Egg Honey
Muscle Fat Liver Kidney
Others
Avilamycin Porcine, poultry, rabbits 1064/2007 50 100 300 200
Bacitracinc Bovine 1478/2001 100
Bacitracin Rabbits 544/2003 150 150 150 150
Cavulanic acid Bovine, porcine 1553/2001 100 100 200 400 200
Colistin All food-producing species 1181/2002 150 150 150 200 50 300
Novobiocin Bovine 2593/1999 50
If no MRL for egg or milk has been established, the substance is not to be used in animals from which eggs or milk are produced for human
consumption.
a Provisional MRL
b Tylvalosin was formerly registered as acetylisovaleryltylosin.
c Other tissues: Annex II (no MRL required)
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Table 2 Overview of the methods referred to in this paper
Type of assay: name and/or indicator organism Intended matrix Reference
Tube test
Bacillus stearothermophilus based tube test Milk [4]
Premi®Test (B. stearothermophilus) and solvent extraction Multiple matrices [5]
Premi®Test (B. stearothermophilus) Poultry tissue fluid [51]
Delvotest® SP-NT and Copan (B. stearothermophilus) Milk [59]
Delvotest® SP-NT (B. stearothermophilus) Milk [60]
Single-plate assay
New Dutch kidney test (B. subtilis) Renal pelvis fluid absorbed on
paper disk
[12]
Belgian kidney test (B. subtilis) Renal pelvis fluid/kidney cortex [13]
B. subtilis plate test Kidney tissue [14]
STOP (B. subtilis) Muscle fluid absorbed with
swab
[27]
CAST (B. megaterium) Kidney fluid absorbed with
swab
[28]
FAST (B. megaterium) bromocresol purple indicator for reduced assay time Kidney fluid absorbed with
swab
[29]
Escherichia coli plate test (specific detection of quinolones) Muscle [39]
Yersinia ruckeri plate test (specific detection of quinolones) Fish [44]
E. coli plate test (specific detection of quinolones) Not specified [40]
Klebsiella pneumoniae plate test (specific detection of quinolones) Egg [42]
K. pneumoniae plate test (specific detection of quinolones) Poultry tissue [43]
Multiplate methods
EU 4-plate test (Kocuria rhizophila and B. subtilis plates
at pH 6, 7.2 + trimethoprim, and pH 8)
Muscle [9]
EU 4-plate test Muscle [18]
EU 4-plate test Muscle [19]
3-plate test (K. rhizophila, B. cereus, and E. coli) for detection and presumptive
identification of tetracylcines, β-lactam, and quinolones
Poultry muscle [20]
Combination of 7 organisms and 5 media Not specified [21]
3-plate test (B. subtilis pH 6, 7.2, and 8) Muscle and kidney tissue [22]
18 combinations of 8 test bacteria, different pH, and additions reversing the
action of specific antibiotics
Muscle and kidney tissue [23]
6-plate method (B. subtilis pH 6 and 7.2, K. rhizophila pH 6 and 8, B. cereus, E. coli) Muscle and kidney tissue [24]
7-plate USDA-FSIS method (B. cereus, B. subtilis, Staphylococcus epidermidis, 2 K.
rhizophila species)
Muscle and poultry tissue [25]
7-plate USDA-FSIS method Muscle [26]
5-plate test STAR (B. subtilis, B. stearothermophilus, B. cereus, K. rhizophila, and E. coli) Milk [31]
6-plate method CPMA (B. subtilis pH 6, 7.2 and 8, B. cereus, K. rhizophila, and E. coli)
including confirmatory solutions
Muscle and kidney tissue [33]
Multiplate assay (B. subtilis pH 7.2 and 8, B. stearothermophilus, additional plates for
presumptive identification)
Milk [34]
Multiplate assay (B. subtilis pH 6, 7.2 and 8, B. cereus, additional plates for presumptive
identification)
Muscle [35]
5-plate test NAT (B. subtilis, B. cereus, B. pumilus, K. rhizophila, and Y. ruckeri) Renal pelvis fluid absorbed on
paper disk
[36]
4-plate method (B. subtilis, B. pumilus, K. rhizophila, Y. ruckeri) Kidney fluid [37]
Method comparison
One-plate test (B. subtilis pH 7) and Premi®Test comparison Kidney fluid [6]
EU 4-plate test and Premi®Test comparison Trout [7]
NAT, STAR, and Premi®Test comparative study Kidney, muscle [38]
Plate assays based on B. subtilis, B. cereus, and E. coli (specific detection of quinolones) Poultry muscle [41]
Plate assay based on Y. ruckeri and Premi®Test (specific detection of quinolones) Poultry muscle and egg [45]
EU 4-plate test, B. stearothermophilus disk assay and Premi®Test comparison Poultry muscle fluid [46]
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Reviewing the activity profiles is a relatively simple way
to achieve preliminary identification [23, 26]. The ultimate
form of it is presented in the Nouws antibiotic test (NAT)
[36]. This method comprises five test plates, each one
specific for one or two groups of antibiotics, with the plate
showing the largest inhibition zone revealing the group
identity of a residue. The method is based on the analysis of
renal pelvis fluid. It uses a format that slightly differs from
most plate tests, as it does not apply samples on top of the
agar layer, but in punch holes which are supplemented with a
plate-specific buffer. This approach yields good sensitivity,
though the procedure becomes more complex, which might
be a disadvantage in terms of robustness. In accordance with
this same principle, postscreening methods for the analysis
of kidney and meat [37, 38] were developed, and are used
for screening of slaughter animals within the framework of
the National Monitoring Program in the Netherlands.
It can be concluded that the increased number of test
plates, required to achieve adequate detection, has resulted
in more laborious methods. However, they bring the
advantage of enhancing the possibilities and the accuracy
of presumptive antibiotic group identification, which may
reduce confirmatory costs and efforts.
Additional methods developed for quinolones
Some of the studies concerning microbial screening
methods do not intend to cover the entire spectrum of
antimicrobial residues, but only a specific group of anti-
biotics. This is particularly true for the quinolones, a major
antibiotic group that only became veterinarily relevant
during the last decade of the twentieth century.
Ellerbroek [39] compared the sensitivity of B. subtilis
BGA and E. coli (Bay) 14 towards enrofloxacin, cipro-
floxacin, and flumequine. He proposed an extension of the
German three-plate (B. subtilis) method with E. coli, which
was found to be 3–30 times more sensitive depending on
the quinolone residue. Similarly, Choi et al. [40] compared
several other E. coli strains with B. subtilis ATCC 3491,
which was the official test organism for antibiotic screening
in Canada. Besides enrofloxacin, ciprofloxacin, and flume-
quine, the study included also sarafloxacin and difloxacin.
For all these residues E. coli ATCC 128 appeared to be
superiorly sensitive and this organism was recommen-
ded for supplementing the existing microbial screening
tests. A third comparative study evaluated the suscep-
tibility of the same organisms as in [39] for ten different
quinolones [41]. Only difloxacin appeared to be detected
more sensitively using B. subtilis as the test organism.
The paper also shows the differences between growth
medium at pH 6 and pH 8. Detection of naldixic acid,
flumequine, oxolinic acid, and difloxacin appeared to be
optimal at pH 6; for the others pH 8 is favorable. It was
concluded that the addition of an E. coli pH 8 test is the
best option to include in existing screening methods.
However, depending on the matrix it might be necessary
to include a pH 6 plate for adequate detection of
flumequine, since the MRL of flumequine in muscle
differs between species (600 μg kg-1 in fish, 400 μg kg-1
in poultry, and 200 μg kg-1 in other species). Most of the
broad-spectrum multiplate methods mentioned in the
previous section comprise a specific E. coli test plate for
quinolone detection, either E. coli (Bay) 14 at pH 6 [20]
or E. coli 11303 at pH 7.2 [23, 24, 33] or pH 8 [31].
Two alternative bacterial species been proposed for
the detection of quinolones, Klebsiella pneumoniae
ATTC 10031 [42, 43] and Yersinia ruckeri NCIMB
13282 [44, 45]. For K. pneumoniae only data on its
sensitivity towards enrofloxacin have been published [42,
43]. The Y. ruckeri assay was originally developed for the
detection of oxolinic acid in fish [44]; the detection
capability of a Y. ruckeri based pH 6.5 assay for several
additional quinolones in egg and poultry muscle was
published later [45]. The Nouws antibiotic test is the only
multiplate method so far that has implemented this species
for quinolone detection [36–38]. It has been claimed that
the use of this organism provides a better balance between
sensitivity towards enrofloxacin and oxolinic acid and
Table 2 (continued)
Type of assay: name and/or indicator organism Intended matrix Reference
EU 4-plate test and Premi®Test comparison (AFNOR validation) Muscle fluid [47]
Premi®Test and B. subtilis and B. cereus based plate methods (specific detection
of tetracyclines)
Muscle(fluid) [49]
FAST, Premi®Test and KISTM (B. stearothermophilus tube test) comparative study Kidney fluid and serum [52]
FAST, Premi®Test and KISTM (B. stearothermophilus tube test) comparative study Kidney fluid and serum [53]
In the first column the type of assay is mentioned, including the indicator organism(s) and (if applicable) the name of the test. The second column
mentions the type of matrix for which the test is intended
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flumequine [45], though a straightforward comparison
between the two species is lacking so far.
Tube tests
From a practical perspective, tube tests form an attractive
alternative to multiplate methods. Almost without exception
these tests use B. stearothermophilus var. calidolactis as the
indicator organism. The only equipment needed is a device
(e.g., garlic press) to obtain tissue fluid and an incubator or
water bath at the appropriate temperature. Assay results are
available within 4 h, and the use of spores instead of
vegetative cells allows prolonged shelf life, which makes
commercial distribution feasible. Initially, commercially
available B. stearothermophilus tube tests were developed
for the analysis of milk, but for several years tests intended
for other animal matrices have also become commercially
available; e.g., Premi®Test (DSM), Explorer (Zeu-Inmuno-
tech), and Kidney Inhibition Swab (KIS™) test (Charm
Sciences). The only test for which a substantial amount of
literature is available is Premi®Test.
B. stearothermophilus is widely used for detection of
antibiotics in milk, because it is very sensitive to what is
considered the most important group of antimicrobials for
this matrix, the β-lactam antibiotics. Popelka et al. [46]
showed that Premi®Test exhibits excellent sensitivity for
penicillin, amoxicillin, ampicillin, oxacillin, and cloxacillin.
The study includes results of poultry muscle samples
originating from animals treated with amoxicillin. Pre-
mi®Test appeared to be capable of detecting residue levels
down to 21 μg kg-1.
Premi®Test recently received AFNOR (French Associa-
tion for Normalization) certification. The AFNOR validation
mark certifies the analytical effectiveness of commercial
methods for a defined field of application, which should be
comparable to the effectiveness of a reference method. The
organization mainly certifies microbiological detection meth-
ods in food and water. Certification of antibiotic detection
methods is limited so far; besides Premi®Test only a receptor
assay for β-lactam antibiotics, beta-STAR (Neogen), has
received an AFNOR certificate.
The results of the validation study, which was performed
by the CRL, have been published [47]. The study comprised
several steps. In the first step, the detection capability of the
test for amoxicillin, ceftiofur, sulfamethazine, OTC, tylosin,
and gentamicin in fortified meat juice samples was analyzed.
Detection of amoxicillin, ceftiofur, and tylosin at their
respective MRLs was satisfactorily, sulfamethazine and
OTC were adequately detected at twice the MRL, but
gentamicin was not. The false-positive rate was fairly high,
with six “doubtful” results out of 40 measurements.
The second step concerned a comparison between
Premi®Test and the EU4pt with incurred muscle samples.
Since this is the French official method for monitoring
muscle samples, it was assigned as the reference method.
Incurred samples containing 750 μg kg-1 tylosin (MRL
100 μg kg-1), 270 μg kg-1 amoxicillin (MRL 50 μg kg-1),
and a combination of 760 ug kg-1OTC and 150 ug kg-1
sulfadimethoxine (MRL for both 100 μg kg-1) were
compared. The method performance was evaluated in terms
of relative accuracy, relative specificity, and relative
sensitivity and it was concluded that the results were
similar, with Premi®Test yielding fewer false-negative and
false-positive results. In more detail Premi®Test detected all
incurred samples, while the EU4pt showed a false-negative
rate of 20% for the amoxicillin and 80% for the tylosin
incurred tissue samples. These results form the major
argument on which the AFNOR certification is based.
From these results it may seem fair to conclude that
Premi®Test performs equally well as or better than the
reference method. However, evaluating the performance of a
method against a reference method that, although it is still
used on a large scale, is widely recognized to be insufficiently
sensitive is arguable. Moreover, the samples that were used for
the comparative study contained residue concentrations that
were considerably higher than “the level of interest,” the
MRL, so performing better than the reference method is no
guarantee of performing adequately at the relevant residue
concentrations. Finally, the number of different residues
evaluated was very limited, which makes the outcome only
of limited value in judging the application as a broad-
spectrum-antibiotic screening method.
Additionally field samples testing positive with either
Premi®Test or an additional B. cereus test were retested by
the CRL using Premi®Test, the EU4pt, and the STAR
method [30, 31]. Besides a disturbingly high false-positive
rate for Premi®Test (62%), this part of the study also
showed clearly that is the STAR method is much more
sensitive than the EU4pt. Since 2006 field laboratories in
France have been authorized to use Premi®Test as a
prescreening, under the condition that all positive results
are reanalyzed with the EU4pt.
Premi®Test claims to be suitable for matrices such as
kidney, fish, eggs, and feed, but literature data on these
matrices is very limited so far. Residue detection in eggs
has only been studied with sulfadimidine [48], and
detection in fish fluid was only tested with four antibiotics
[7]. A much more extensive study, including the compar-
ison with a one-plate B. subtilis test, was performed with 18
different antibiotics in kidney fluid [6]. Using kidney as a
matrix may be an advantage, since the MRLs of several
antibiotics are higher for this organ. Initially the detection
capability was determined using antibiotic standard solu-
tions. The sensitivity for most of the antibiotics tested
appeared to be below the kidney MRL, except for
chlortetracycline, sulfamethazine, streptomycin, and flume-
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quine (and the banned residue chloramphenicol). In
particular, for β-lactam antibiotics and sulfonamides the
Premi®Test outperformed the one-plate test. However,
when the same comparison was repeated using fortified
kidney fluid samples, a considerable matrix effect was
observed. The sensitivity of Premi®Test for β-lactam
antibiotics remains below their MRLs, but with exception
of doxycycline, all other antimicrobials were no longer
detected adequately.
Okerman et al. [49] compared several methods, including
Premi®Test, for the detection of tetracyclines in animal tissue.
The Premi®Test results of chicken muscle spiked with
100 μg kg-1 of all four veterinarily used tetracyclines were
negative. The study included the analysis of incurred
samples. Unfortunately the highest doxycycline concentration
(108.8 μg kg-1) yielded a negative Premi®Test result, so no
conclusions regarding the detection limit for this compound
could be made. OTC incurred samples were available at a
much wider range and with this residue Premi®Test gave
a positive result between 192.8 and 427 μg kg-1. Using a
B. cereus based plate test detection of OTC at half the MRL
appeared feasible. It should be mentioned that all the
microbial test methods evaluated in this study were out-
competed by a commercial receptor test (Tetrasensor).
A comparison between two multiplate tests and Pre-
mi®Test also revealed insufficient sensitivity of Premi®Test
with respect to the detection of tetracyclines [38]. Analysis
of 591 slaughter animals yielded four MRL violations, of
which three were tetracyclines that remained undetected by
Premi®Test. A study on quinolone detection in poultry and
eggs by the same group [45] showed that Premi®Test is
also not suitable for this group of antibiotic residues, as all
compounds tested remained undetected at their MRL.
Stead et al. [5] proposed an acetonitrile/acetone extrac-
tion to enhance the sensitivity of Premi®Test. Detection
limits for a broad range of antibiotics and matrices were
presented using this sample pretreatment. An advantage of
using ampoule-based tests is the potential for objective
automated processing of the results, using scanner technol-
ogy as an alternative to subjective visual assessment [50].
Like one-plate tests, a tube test lacks the possibility for
group identification. However, secondary screening for
antibiotic group identification by repeating the assay
supplemented with 4-aminobenzoate or β-lactamase can
selectively identify the presence of sulfonamides or β-
lactams [5]. In the same way, group identification of
tetracyclines can be obtained after addition of a calcium-
containing buffer [51].
The performances of Premi®Test and a similar B.
stearothermophilus tube test, KISTM, were evaluated to
asses the possibility to replace FAST [29], a B. mega-
therium one-plate test operated by the US Food Safety and
Inspection Service [52, 53]. In addition to kidney fluid,
which is the test matrix for FAST, also serum was tested
since it would allow antemortem screening. KIS™ is
specifically designed for the analysis of kidney and in
practice employs a disposable swab format, but for this
study samples were directly pipetted onto the test tube.
Initially eight antibiotics (penicillin, sulfadimethoxine,
OTC, tylosin, danofloxacin, streptomycin, neomycin, and
spectinomycin) were tested [52]. As may be expected from
the fact that they exploit the same test organism, differences
in the results of the two B. stearothermophilus tests were
only minor. FAST appeared significantly more sensitive for
the aminoglycosides, but for most of the other residues the
B. stearothermophilus tests show better sensitivity. KIS™
showed a considerable number of false-positive responses,
but this maybe attributed to the fact that the kidney juice
samples were not subjected to a preincubation step at 80°C.
This step is included in the Premi®Test protocol when one
is analyzing kidney (and egg) to inactivate natural growth-
inhibiting compounds.
Subsequently a very thorough study was carried out on
suspect carcasses obtained from a meat inspection program
[53]. Kidney and serum were subjected to each of the three
microbial tests and were also analyzed by liquid chroma-
tography–tandem mass spectrometry. From an analytical
perspective, the range of compounds and concentrations
found was somewhat disappointing. Only 39 out of 235
carcasses contained residues, mainly dihydrostreptomycin,
penicillin, OTC, pirlimycin, and desfurylceftiofur cysteine
disulfide, at very low levels. However, the three samples
showing concentrations above US tolerance levels were
effectively detected by both KISTM and Premi®Test, while
FAST missed a sample containing 141 µg kg-1 sulfametha-
zine. It should be noted that the relatively low sensitivity of
B. stearothermophilus for tetracyclines is not an issue in the
US situation, where tolerance levels for tetracycline in
kidney were set at 12,000 μg kg-1.
It can be concluded that tube tests can be used as a
broad-spectrum screening method, but that in many cases
parallel tests covering, for example, tetracycline and
quinolone residues will be required.
Method validation and proficiency testing
Determining the suitability and applicability of a method
for a specific matrix is obviously an important issue. It has
probably become clear from the previous sections that it is
difficult to compare the performances of individual meth-
ods on the basis of literature data, because factors such as
the type of matrix and the specific residues investigated
differ between studies. To come to more standardized
procedures for method evaluation, the European Commis-
sion has issued a decision on method validation, 2002/657/
EC [54], which describes how analytical methods should be
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validated according to common procedures and perfor-
mance criteria. A method has to fulfill a defined subset of
performance criteria, depending on whether it concerns a
qualitative or a quantitative method, and a screening or
confirmatory method (Table 3). Qualitative screening
methods, such as the microbiological antibiotic detection
methods, should be validated with respect to the following
parameters: detection capability (CCβ), specificity/selectiv-
ity, ruggedness, and stability.
Detection capability
Two main dilemmas emerge when considering the valida-
tion of the detection capability of a broad-spectrum
microbial screening method; the type of sample (matrix)
and the number of compounds that should be assessed.
Although characterization with antibiotic standard sol-
utions is relatively simple and provides valuable informa-
tion on the bioactivity of individual compounds within a
group, CCβ values obtained with such an approach cannot
be considered representative for practical samples [6, 24,
45, 55]. The presence of an animal matrix may affect the
detection capability of a method through various factors,
such as the addition of growth components, local pH
change, degradation, and protein binding. Validation should
therefore (also) be performed with the matrix samples.
Fortifying liquid matrices such as milk and egg is
straightforward, but validating the detection capability of
a method for meat or kidney is somewhat more complicat-
ed. For methods based on the detection of meat or kidney
fluid, fortification is relatively easy, although two different
approaches are being employed: fortification extracted fluid
[6, 49] and fortification of tissue with subsequent extraction
[5, 37]. Most methods for the screening of meat and kidney,
however, rely on the analysis of intact pieces of tissue.
Although the use of frozen pieces of fortified minced tissue,
referred to as “simulated tissue,” has been reported [32], it
remains difficult to find a proper fortification strategy for
this type of test.
It would be highly preferable, especially with tests
analyzing intact tissue, to assess the detection capability
using incurred samples. Some studies evaluating the
performance of microbial screening methods use tissues
originating from animal medication experiments [47, 49,
56], but the production of incurred materials for each
antibiotic at the appropriate concentration is a difficult and
expensive task. Alternatively, samples originating from
monitoring programs have been used for method evaluation
[20, 22–24, 38, 53, 57]. The most fruitful approach was to
use emergency-slaughtered animals for which medication
information indicates they were slaughtered before the end
of the withdrawal period [22]. In general, however, these
studies yielded only limited numbers of positive samples
representing only a very limited group of substances,
raising the question whether other residues were not
present, or were not found because the method was too
insensitive.
It has been proposed to limit the number of compounds
to be validated for broad-spectrum methods by assigning
“representative compounds” [37, 58]. It is assumed that one
or two compounds within an antibiotic group can act as
representatives for the entire group. This may be a
legitimate assumption, but it should be treated with care.
The relative bioactivity of compounds within a group may
differ when they are exposed to a different test bacterium.
Assuming that the representative compound should be the
one that is detected least sensitively with respect to its
MRL, also the fact that the MRLs vary between matrices
may have consequences.
So far only a few microbial screening methods claim to
have been validated “according to 2002/657/EC” [36, 37,
51, 59]. All of them determine CCβ using fortified
concentration series. CCβ is determined as the lowest
concentration for which 20 measurements (or more) give
less than 5% false-negative results, so it would probably be
more correct to state that CCβ is smaller than the
established concentration.
Other validation criteria
The other criteria for qualitative screening methods,
specificity/selectivity, ruggedness, and stability, can be
interpreted in many ways. Pikkemaat et al. [36, 37]
determined specificity by analyzing high (2–5 times the
Table 3 Performance characteristics that should be determined in method validation according to 2002/657/EC
Detection
limit CCß
Decision
limit CCa
Trueness/
recovery
Precision Selectivity/
specificity
Applicability/
ruggedness/stability
Qualitative methods Screening + - - - + +
Confirmatory + + - - + +
Quantitative methods Screening + - - + + +
Confirmatory + + + + + +
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MRL) concentrations of all residues on each of the test
plates. LeBreton et al. [59] claimed that a microbial
inhibition tube test by definition is not specific, and only
additional blank milk samples were tested. The same assay
was validated according to the ISO/IDF 183 guideline as
well [60]. In this study specificity was tested as the
susceptibility to interfering substances (differing levels of
fat, high somatic cell count, different species, etc.).
Ruggedness was defined by LeBreton et al. [59] as the
reproducibility using different batches of tests, two ana-
lysts, different days, and spikes from different standard
solutions. Tests were found rugged under the assumption
that the result is judged according to a positive control.
More specifically determined ruggedness aspects concerned
variation in application volume and incubation temperature
[60]. Ruggedness can also be shown by successful
interlaboratory assessment [51].
Finally, the 2002/657/EC parameter stability, although in
practice it is a very relevant aspect, forms a disputable
demand. Since it is independent of the method used for the
analysis, it cannot be considered a characteristic of a method.
Assessing stability with a qualitative method is even more
disputable, as the type of method implies that no absolute
values can be assigned. Nevertheless Okerman et al. [41]
analyzed the stability of frozen stock solutions of several β-
lactams, tetracyclines, and quinolones using a B. subtilis plate
assay. Under the assumption that a reduction more than 25%
was significant, it was concluded that tetracycline, OTC,
ceftiofur, and cefapirin were stable for less than 6 months,
while amoxicillin and penicillin already showed a significant
reduction after 2 months. The stability of antibiotic residues
may vary between matrices, and results with other storage
temperatures will also be relevant, as in practice samples are,
for example, stored at 4°C for several days. This problem has
been recognized by the CRL, who proposed that “Stability
data can be extracted from other laboratories’ studies,
performed with other analytical methods, because they do
not depend on the method used for analysis” [61].
Proficiency testing
Proficiency testing is another closely related quality control
aspect, which is not in the 2002/657/EC criteria, but was
prescribed in the earlier Commission Decision 98/179/EC,
which states that “approved laboratories must prove their
competence by regular and successful participation in
adequate proficiency testing schemes recognized or organized
by the national or Community reference laboratories” [62].
In contrast to other microbiological methods, currently
there are no regular proficiency testing programs opera-
tional for microbial residue screening methods, while these
are considered highly necessary to reveal the inevitable
shortcomings in this area. Proficiency testing is available
for chemical analysis of antibiotics, but the samples used in
these studies often combine several residues in one sample,
which will yield an additional or even synergistic effect
when analyzed with effect-based microbial methods.
Moreover, the materials are often homogenized, and
therefore unsuitable for tests that operate on intact tissue.
In 2005 the CRL organized a proficiency test among 22
laboratories of which 21 performed microbiological screen-
ing [17]. Even though the residue concentrations in that
study (195 μg kg-1 danofloxacin, 376 μg kg-1 tylosin, and a
combination of 227 μg kg-1 OTC and 343 μg kg-1
sulfadimethoxine, along with two blank samples) were
considerably above the MRLs for these compounds, only
13 laboratories correctly identified all three positive
samples; additionally, five more laboratories produced
false-positive results. This outcome may even be consid-
ered optimistic with respect to the situation in practice,
since the laboratories involved were national reference
laboratories, while in many countries the initial screening is
delegated to routine field laboratories.
Conclusions
This paper provides an overview of the developments in the
field of microbial screening methods for antibiotic residues
in slaughter animals since the early 1990s, when the
establishment of MRLs at levels below the sensitivity of
the established and generally applied methods made us
reconsider these existing screening methods.
Although the literature may show improved methods, the
lack of validation data on incurred samples hampers an
accurate evaluation of their true performance. It also
remains difficult to get a clear picture of the extent to
which improved methods have actually been implemented
in practice. The results of a proficiency test organized
among the EU national reference laboratories in 2005
showed that in an alarming number of laboratories the
screening methods used were not sufficiently sensitive. The
EU Standing Committee on the Food Chain and Animal
Health produces a yearly report on the outcome of the
national monitoring programmes [63]. For B1 substances
the percentage of noncompliant results remains rather
stable, around 0.2-0.3%. Considering the shortcomings of
the currently applied screening methods, this figure is likely
to be a serious underestimation of the actual noncompliance
rate. It should be noted, however, that these data also
include results of additional control programs for which the
result of the microbial test is sufficient to reject the carcass.
For some categories of animals these results represent over
50% of the total noncompliant results.
The fact that different methods are used and also target
organs differ makes it impossible to compare the results
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between countries. One could argue that the change from
prescribing routine or reference methods to an approach in
which performance criteria and procedures for the valida-
tion of detection methods are established (2002/657/ EC)
has not made this easier. Moreover, despite the attempt to
standardize validation procedures, 2002/657/EC still leaves
a lot of room for interpretation and is not considered very
suitable for microbial methods.
Chemical methods generally were considered too spe-
cific and expensive to be applied as an initial screening.
However, liquid chromatography–tandem mass spectrome-
try methods capable of simultaneous detection of multiple
classes of antibiotics are increasingly becoming available
[52, 64–66] and may in some situations represent a cost-
effective alternative. It should certainly be considered
feasible for use within a national reference laboratory, as,
for example, is already effectuated in Sweden (K. Granelli,
personal communication) However, in particular for those
countries that rely upon a monitoring infrastructure includ-
ing dozens of routine field laboratories, it can be concluded
that there is still a strong need for the development and
implementation of adequate microbial screening methods,
and more regular proficiency testing to reveal the short-
comings in the currently applied screening methods. It
should be realized that these methods form the first line of
defense in antibiotic residue monitoring, so it is essential to
have accurate screening methods in place.
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medium, provided the original author(s) and source are credited.
References
1. Myers RP (1964) Rev Environ Contam Toxicol 7:11–36
2. Mitchell JM, Griffiths MW, McEwen SA, McNab WB, Yee AJ
(1998) J Food Prot 61:742–756
3. Suhren G, Heeschen W (1996) Nahrung 40:1–7
4. Vermunt AEM, Stadhouders J, Loeffen GJM, Bakker R (1993)
Neth Milk Dairy J 47:31–40
5. Stead S, Sharman M, Tarbin JA, Gibson E, Richmond S, Stark J,
Geijp E (2004) Food Addit Contam 21:216–221
6. Cantwell H, O’Keeffe M (2006) Food Addit Contam 23:120–125
7. Kilnic B, Meyer C, Volker H (2007) Int J Food Sci Technol
42:635–628
8. Nouws JFM, Schothorst M, Ziv G (1979) Arch Lebensm Hyg
30:4–8
9. Bogaerts R, Wolf F (1980) Fleischwirtsch 60:672–673
10. van Schothorst M (1969) Thesis, Utrecht University
11. Tang JS, Gillevet PM (2003) Int J Syst Evol Microbiol 53:995–997
12. Nouws JFM, Broex NJG, Den Hartog JMP, Driessens F (1988)
Arch Lebensm Hyg 39:135–138
13. Koenen-Dierick K, Okerman L, De Zutter L, Degroodt JM, Van
Hoof J, Srebrnik S (1995) Food Addit Contam 12:77–82
14. Nolan M, Dooley M, Nugent A, O’Keeffe M (2000) In:
Proceedings of Euroresidue IV conference, pp 781–785
15. EU Council (1990) Off J Eur Union L224:1–8
16. EU Council (1996) Off J Eur Union L125:10–32
17. Sanders P, Fuselier R, Juhel M, Gaudin V (2006) CRL report:
proficiency study for the analysis of antibiotic residues in muscle
tissue. Community Reference Laboratory for Antimicrobial
Residues in Food, AFSSA Fougères
18. Currie D, Lynas L, Kennedy DG, McCaughey WJ (1998) Food
Addit Contam 15:651–660
19. Okerman L, van Hoof J, Debeuckelaere W (1998) J AOAC Int
81:51–56
20. Okerman L, Croubels S, De Baere S, Van Hoof J, De Backer P,
De Brabander H (2001) Food Addit Contam 18:385–393
21. Tsai C-E, Kondo F (2001) J Food Prot 64:361–366
22. Myllyniemi A-L, Rannikko R, Lindfors E, Niemi A, Backman C
(2000) Food Addit Contam 17:991–1000
23. Myllyniemi A-L, Rintala R, Backman C, Niemi A (1999) Food
Addit Contam 16:339–351
24. Myllyniemi A-L, Nuotio L, Lindfors E, Rannikko R, Niemi A,
Backman C (2001) Analyst 126:641–646
25. USDA-FSIS (2007) Laboratory guidebook chapter 34.2. http://
www.fsis.usda.gov/PDF/MLG_34_02.pdf
26. Calderon V, Gonzalez J, Diez P, Berenguer JA (1996) Food Addit
Contam 13:13–19
27. Johnston W, Reamer RH, Harris EW, Fugate HG, Schwab B
(1981) J Food Prot 44:828–831
28. Dey BP, Reamer P, Thaker NH, Thaler AM (2005) J AOAC Int
88:440–446
29. Dey BP, Thaker NH, Bright SA, Thaler AM (2005) J AOAC Int
88:447–454
30. Fuselier R, Cadieu N, Maris P (2000) In: Proceedings of
Euroresidue IV conference, pp 444–448
31. Gaudin V, Maris P, Fuselier R, Ribouchon J-L, Cadieu N, Rault A
(2004) Food Addit Contam 21:422–433
32. Gaudin V, Verdon E, Sanders P (2008) In: Proceedings of
Euroresidue VI conference, pp 1007–1012
33. Ferrini AM,Mannoni V, Aureli P (2006) Food Addit Contam 23:16–24
34. Aureli P, Ferrini AM, Mannoni V (1996) Food Control 7:65–168
35. Ferrini AM, Mannoni V, Aureli P (1997) Arch Lebensmhyg
48:133–135
36. Pikkemaat MG, Oostra-Van Dijk S, Schouten J, Rapallini M, van
Egmond HJ (2008) Food Control 19:781–789
37. Pikkemaat MG, Oostra-Van Dijk S, Schouten J, Rapallini M,
Kortenhoeven L, van Egmond HJ (2009) Food Control 20:771–777
38. Pikkemaat MG, Rapallini MLBA, Oostra-Van Dijk S, Elferink
JWA (2009) Anal Chim Acta 637:298–304
39. Ellerbroek L (1991) Fleischwirtsch 71:187–189
40. Choi J, Yee AJ, Thompson D, Samoluk J, Mitchel M (1999) J
AOAC Int 82:1407–1412
41. Okerman L, Noppe H, Cornet V, De Zutter L (2007) Food Addit
Contam 24:252–257
42. Donoghue DJ, Schneider MJ (2003) J AOAC Int 86:669–674
43. Schneider MJ, Donoghue DJ (2004) Poult Sci 83:830–834
44. Barker GA (1994) Aquaculture 127:83–90
45. Pikkemaat MG, Mulder PPJ, Elferink JWA, De Cocq A, Nielen
MWF, van Egmond HJ (2007) Food Addit Contam 24:842–850
46. Popelka P, Nagy J, Germuska R, Marcincak S, Jevinova P, de Rijk
A (2005) Food Addit Contam 22:557–562
47. Gaudin V, Juhel-Gaugain M, Mortain J-P, Sanders P (2008) Food
Addit Contam 25:1451–1464
48. Hussein K, Marcincak S, Mate D, Kozarova I, Sokol J, Zdolec N
(2005) Acta Vet (Beogr) 55:493–500
49. Okerman L, Croubels S, Cherlet M, De Wasch K, De Backer P,
Van Hoof J (2004) Food Addit Contam 21:145–153
904 M.G. Pikkemaat
50. Stead S, Richmond S, Sharman M, Stark J, Geijp E (2005) Anal
Chim Acta 529:83–85
51. Stead SL, Caldow M, Sharma A, Ashwin HM, Sharman M, de
Rijk A, Stark J (2007) Food Addit Contam 24:583–589
52. Schneider MJ, Lehotay SJ (2008) Anal Bioanal Chem 390:1775–
1779
53. Schneider MJ, Mastovska K, Lehotay SJ, Lightfield AR, Kinsella
B, Shultz CE (2009) Anal Chim Acta 637:290–297
54. EU Commission (2002) Off J Eur Union L221:8–36
55. Okerman L, De Wasch K, Van Hoof J (1998) Analyst 123:2361–
2365
56. Croubels S, Baert K, Okerman L, Robbrecht V, Aerden L, De
Backer P (1999) Vlaams Diergeneeskd Tijdschr 68:22–26
57. De Wasch K, Okerman L, Croubels S, De Brabander H, Van Hoof
J, De Backer P (1998) Analyst 123:2737–2741
58. Gaudin V, Sanders P (2005) Draft guide for analytical validation
of screening methods, version 2, CRL internal document 19/10/
2005. Community Reference Laboratory for Antimicrobial Resi-
dues in Food, AFSSA Fougères
59. Le Breton M-H, Savoy-Perroud M-C, Diserens J-M (2007) Anal
Chim Acta 586:280–283
60. Stead SL, Ashwin H, Richmond SF, Sharman M, Langeveld PC,
Barendse JP, Stark J, Keely BJ (2008) Int Dairy J 18:3–11
61. Gaudin V, Sanders P, Gowik P, Uhlig S (2007) Draft guide for
analytical validation of screening methods, version 4. CRL
internal document Sept 2007. Community Reference Laboratory
for Antimicrobial Residues in Food, AFSSA Fougères
62. European Commission (1998) Off J Eur Union L65:31–34
63. European Commission (2009) EUROPA—food safety—chemical
safety of food—residues of veterinary medicinal products—
control and monitoring. http://ec.europa.eu/food/food/chemical
safety/residues/control_en.htm
64. Yamada R, Kozono M, Ohmori T, Morimatsu F, Kitayama M
(2006) Biosci Biotechnol Biochem 70:54–65
65. Granelli K, Branzell C (2007) Anal Chim Acta 586:289–295
66. Stolker AAM, Rutgers P, Oosterink E, Lasaroms JJP, Peters RJB,
van Rhijn JA, Nielen MWF (2008) Anal Bioanal Chem
391:2309–2322
Microbial screening methods for detection of antibiotic residues 905
